CN107072207A - 经取代的哌啶化合物 - Google Patents
经取代的哌啶化合物 Download PDFInfo
- Publication number
- CN107072207A CN107072207A CN201580060918.8A CN201580060918A CN107072207A CN 107072207 A CN107072207 A CN 107072207A CN 201580060918 A CN201580060918 A CN 201580060918A CN 107072207 A CN107072207 A CN 107072207A
- Authority
- CN
- China
- Prior art keywords
- cancer
- cell
- carcinoma
- alkyl
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*[C@@](C)[C@@](C1)[C@]11[C@](C)CC(C)(C)C1 Chemical compound C*[C@@](C)[C@@](C1)[C@]11[C@](C)CC(C)(C)C1 0.000 description 20
- IFTRQJLVEBNKJK-UHFFFAOYSA-N CCC1CCCC1 Chemical compound CCC1CCCC1 IFTRQJLVEBNKJK-UHFFFAOYSA-N 0.000 description 1
- ZTBOOXFVPVFABE-CJDLMENISA-N CCN1CCC(CS(N([C@H](CC2)C3)[C@@H]2C[C@H]3NC(c2n[o]c(C3CC3)c2)=O)(=C)=O)CC1 Chemical compound CCN1CCC(CS(N([C@H](CC2)C3)[C@@H]2C[C@H]3NC(c2n[o]c(C3CC3)c2)=O)(=C)=O)CC1 ZTBOOXFVPVFABE-CJDLMENISA-N 0.000 description 1
- XNVYLERJESNUTK-GBMJPCLJSA-N CCOC(/C(/C=N/C)=C/c(cc1)ccc1O)=O Chemical compound CCOC(/C(/C=N/C)=C/c(cc1)ccc1O)=O XNVYLERJESNUTK-GBMJPCLJSA-N 0.000 description 1
- WSLSIFGLYKRFKV-WPRPVWTQSA-N C[C@@H](C1)NCC[C@@H]1NC(c1n[o]c(C2CC2)c1)=O Chemical compound C[C@@H](C1)NCC[C@@H]1NC(c1n[o]c(C2CC2)c1)=O WSLSIFGLYKRFKV-WPRPVWTQSA-N 0.000 description 1
- VKDNZBSJSJBXRQ-UWVGGRQHSA-N C[C@@H]1NCC[C@H](CNC(c2n[o]c(C3CC3)c2)=O)C1 Chemical compound C[C@@H]1NCC[C@H](CNC(c2n[o]c(C3CC3)c2)=O)C1 VKDNZBSJSJBXRQ-UWVGGRQHSA-N 0.000 description 1
- OGIPSHDJYIEDKG-VEDVMXKPSA-N C[C@H](CC(CC1)N)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CC(CC1)N)N1C(OC(C)(C)C)=O OGIPSHDJYIEDKG-VEDVMXKPSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048771P | 2014-09-10 | 2014-09-10 | |
| US62/048,771 | 2014-09-10 | ||
| US201462078845P | 2014-11-12 | 2014-11-12 | |
| US62/078,845 | 2014-11-12 | ||
| US201562146790P | 2015-04-13 | 2015-04-13 | |
| US62/146,790 | 2015-04-13 | ||
| PCT/US2015/049235 WO2016040515A1 (en) | 2014-09-10 | 2015-09-09 | Substituted piperidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107072207A true CN107072207A (zh) | 2017-08-18 |
Family
ID=55459535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580060918.8A Pending CN107072207A (zh) | 2014-09-10 | 2015-09-09 | 经取代的哌啶化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10577363B2 (enExample) |
| EP (1) | EP3193605A4 (enExample) |
| JP (1) | JP2017528464A (enExample) |
| KR (1) | KR20170047397A (enExample) |
| CN (1) | CN107072207A (enExample) |
| AU (1) | AU2015315182A1 (enExample) |
| BR (1) | BR112017004589A2 (enExample) |
| CA (1) | CA2960280A1 (enExample) |
| EA (1) | EA201790327A1 (enExample) |
| IL (1) | IL250888A0 (enExample) |
| MX (1) | MX2017002986A (enExample) |
| SG (2) | SG10201901189SA (enExample) |
| WO (1) | WO2016040515A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111683945A (zh) * | 2018-01-26 | 2020-09-18 | 爱杜西亚药品有限公司 | Cxcr7受体拮抗剂(3s,4s)-1-环丙基甲基-4-{[5-(2,4-二氟-苯基)-异噁唑-3-羰基]-氨基}-哌啶-3-羧酸(1-嘧啶-2-基-环丙基)-酰胺的结晶型 |
| CN114702552A (zh) * | 2022-03-11 | 2022-07-05 | 苏州思萃免疫技术研究所有限公司 | mTORC2抑制剂 |
| WO2024067708A1 (zh) * | 2022-09-30 | 2024-04-04 | 苏州阿尔脉生物科技有限公司 | 草酸胺类衍生物、包含其的药物组合物及其医药用途 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015315167A1 (en) | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Isoxazole carboxamide compounds |
| CA2960271A1 (en) | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Substituted cyclohexylamine compounds |
| JP2017528460A (ja) * | 2014-09-10 | 2017-09-28 | エピザイム インコーポレイテッド | 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド |
| EP3193600A4 (en) | 2014-09-10 | 2018-05-23 | Epizyme, Inc. | Smyd inhibitors |
| CN114874131B (zh) * | 2015-02-27 | 2025-03-25 | 海洋规划生物工厂株式会社 | Kakeromycin及其衍生物的制造方法 |
| LT3490986T (lt) * | 2016-07-28 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Piperidino cxcr7 receptoriaus moduliatoriai |
| WO2018151678A1 (en) * | 2017-02-15 | 2018-08-23 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
| JP7425793B2 (ja) | 2018-10-29 | 2024-01-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用 |
| MY206745A (en) | 2018-10-29 | 2025-01-04 | Boehringer Ingelheim Int | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| CN114761082A (zh) | 2019-09-30 | 2022-07-15 | 日本化学药品株式会社 | 氮杂环庚烷衍生物 |
| WO2025133989A1 (en) * | 2023-12-20 | 2025-06-26 | Alt-Bio Pte. Ltd. | Smyd modulators and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050250792A1 (en) * | 1999-08-24 | 2005-11-10 | Stephen Thom | Substituted piperidine compounds useful as modulators of chemokine receptor activity |
| CN101124203A (zh) * | 2004-12-20 | 2008-02-13 | 阿斯利康(瑞典)有限公司 | 化合物 |
| WO2008137834A2 (en) * | 2007-05-04 | 2008-11-13 | Osi Pharmaceuticals, Inc. | Crystal structure of smyd3 protein |
| CN103153954A (zh) * | 2010-08-06 | 2013-06-12 | 阿斯利康(瑞典)有限公司 | N-酰基磺酰胺凋亡促进剂 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1228288B (it) * | 1989-01-09 | 1991-06-07 | Zambon Spa | Composti ad attivita' antiserotoninica |
| PE20091093A1 (es) * | 2007-12-03 | 2009-08-25 | Takeda Pharmaceutical | Compuesto heterociclico que contiene nitrogeno y su uso |
| EP2651417B1 (en) * | 2010-12-16 | 2016-11-30 | Calchan Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
| JP2017528460A (ja) * | 2014-09-10 | 2017-09-28 | エピザイム インコーポレイテッド | 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド |
| EP3193600A4 (en) | 2014-09-10 | 2018-05-23 | Epizyme, Inc. | Smyd inhibitors |
| AU2015315177A1 (en) | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Substituted pyrrolidine carboxamide compounds |
| WO2016040504A1 (en) | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Substituted pyrrolidine compounds |
| CA2960271A1 (en) | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Substituted cyclohexylamine compounds |
| AU2015315167A1 (en) * | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Isoxazole carboxamide compounds |
-
2015
- 2015-09-09 CN CN201580060918.8A patent/CN107072207A/zh active Pending
- 2015-09-09 CA CA2960280A patent/CA2960280A1/en not_active Abandoned
- 2015-09-09 EA EA201790327A patent/EA201790327A1/ru unknown
- 2015-09-09 SG SG10201901189SA patent/SG10201901189SA/en unknown
- 2015-09-09 WO PCT/US2015/049235 patent/WO2016040515A1/en not_active Ceased
- 2015-09-09 US US15/510,588 patent/US10577363B2/en active Active
- 2015-09-09 SG SG11201701597RA patent/SG11201701597RA/en unknown
- 2015-09-09 BR BR112017004589A patent/BR112017004589A2/pt not_active Application Discontinuation
- 2015-09-09 AU AU2015315182A patent/AU2015315182A1/en not_active Abandoned
- 2015-09-09 EP EP15840497.0A patent/EP3193605A4/en not_active Withdrawn
- 2015-09-09 KR KR1020177009316A patent/KR20170047397A/ko not_active Withdrawn
- 2015-09-09 MX MX2017002986A patent/MX2017002986A/es unknown
- 2015-09-09 JP JP2017513207A patent/JP2017528464A/ja active Pending
-
2017
- 2017-03-02 IL IL250888A patent/IL250888A0/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050250792A1 (en) * | 1999-08-24 | 2005-11-10 | Stephen Thom | Substituted piperidine compounds useful as modulators of chemokine receptor activity |
| CN101124203A (zh) * | 2004-12-20 | 2008-02-13 | 阿斯利康(瑞典)有限公司 | 化合物 |
| WO2008137834A2 (en) * | 2007-05-04 | 2008-11-13 | Osi Pharmaceuticals, Inc. | Crystal structure of smyd3 protein |
| CN103153954A (zh) * | 2010-08-06 | 2013-06-12 | 阿斯利康(瑞典)有限公司 | N-酰基磺酰胺凋亡促进剂 |
Non-Patent Citations (1)
| Title |
|---|
| FENG LIU ET.AL.: "Exploiting an Allosteric Binding Site of PRMT3 Yields Potent and Selective Inhibitors", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111683945A (zh) * | 2018-01-26 | 2020-09-18 | 爱杜西亚药品有限公司 | Cxcr7受体拮抗剂(3s,4s)-1-环丙基甲基-4-{[5-(2,4-二氟-苯基)-异噁唑-3-羰基]-氨基}-哌啶-3-羧酸(1-嘧啶-2-基-环丙基)-酰胺的结晶型 |
| CN111683945B (zh) * | 2018-01-26 | 2023-11-10 | 爱杜西亚药品有限公司 | Cxcr7受体拮抗剂的结晶型 |
| CN114702552A (zh) * | 2022-03-11 | 2022-07-05 | 苏州思萃免疫技术研究所有限公司 | mTORC2抑制剂 |
| WO2023169125A1 (zh) * | 2022-03-11 | 2023-09-14 | 苏州思萃免疫技术研究所有限公司 | mTORC2抑制剂 |
| CN114702552B (zh) * | 2022-03-11 | 2024-05-31 | 苏州思萃免疫技术研究所有限公司 | mTORC2抑制剂 |
| WO2024067708A1 (zh) * | 2022-09-30 | 2024-04-04 | 苏州阿尔脉生物科技有限公司 | 草酸胺类衍生物、包含其的药物组合物及其医药用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016040515A1 (en) | 2016-03-17 |
| US10577363B2 (en) | 2020-03-03 |
| EP3193605A4 (en) | 2018-04-18 |
| EA201790327A1 (ru) | 2017-10-31 |
| CA2960280A1 (en) | 2016-03-17 |
| AU2015315182A1 (en) | 2017-03-16 |
| US20170362217A1 (en) | 2017-12-21 |
| BR112017004589A2 (pt) | 2018-01-23 |
| SG10201901189SA (en) | 2019-03-28 |
| IL250888A0 (en) | 2017-04-30 |
| JP2017528464A (ja) | 2017-09-28 |
| SG11201701597RA (en) | 2017-03-30 |
| EP3193605A1 (en) | 2017-07-26 |
| MX2017002986A (es) | 2017-10-24 |
| KR20170047397A (ko) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107072207A (zh) | 经取代的哌啶化合物 | |
| CN107072205B (zh) | Smyd抑制剂 | |
| JP7041198B2 (ja) | Ｊａｋ阻害剤である５－クロロ－２－ジフルオロメトキシフェニルピラゾロピリミジン化合物 | |
| US10435399B2 (en) | HDAC6 inhibitory heterocyclic compound | |
| CN102695710B (zh) | 三环吡唑胺衍生物 | |
| CN115956075A (zh) | 用于治疗与pi3k调节相关的疾病的磷酸肌醇3-激酶(pi3k)的变构色烯酮抑制剂 | |
| WO2019158019A1 (zh) | 嘧啶并环化合物及其制备方法和应用 | |
| CN110621670B (zh) | 作为布鲁顿氏酪氨酸激酶的抑制剂的苯并氮杂卓类似物 | |
| CN112272670A (zh) | 含二并环类衍生物抑制剂、其制备方法和应用 | |
| EA028890B1 (ru) | Гетероциклиламины как ингибиторы pi3k | |
| JP2023549360A (ja) | Ｂｔｋ阻害剤としてのピラゾロ［１，５－ａ］ピラジン誘導体 | |
| JP2018510135A (ja) | ＲＯＲγＴ阻害剤としての置換ピラゾール化合物及びその使用 | |
| CA2960273A1 (en) | Substituted pyrrolidine compounds | |
| CN116670123A (zh) | 芳香杂环类化合物、药物组合物及其应用 | |
| TW202517653A (zh) | 治療自體免疫疾病之大環 | |
| CA3173569C (en) | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease | |
| CN117425654A (zh) | 2,8-二氮杂螺[4.5]癸烷化合物 | |
| MD4313293T2 (ro) | Derivati de tetrahidrotienopiridine ca inhibitori DDR | |
| HK40036075A (en) | Inhibitor containing bicyclic ring derivative, and preparation method and uses therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170818 |
|
| WD01 | Invention patent application deemed withdrawn after publication |